reposit
report limit sole use client wolf research pleas refer disclosur section locat end report analyst
certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc
valu
valuat converg growth cheaper wait risk view
posit shift sharpli given week
yieldfcf compound-annual-growth-rate dispers substanti
tool dental valuat diverg significantli pandem
ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool dental reposit rate chang detail come
tool dental valuat diverg significantli pandem
top pick upgrad op pp downgrad brkr/mtd pp
currentcurrentpriorcurr pricecurr wolf px target versu chang prior epsconsensu vs current epstickerpriceratingratingtargetcurr crazi idea
tool dental valuat diverg significantli pandem agre structur prospect
differ overdon
compani data factset price wolf research
 discount dental compar ntm p-e premium tool ntm price-to-earnings premium dental ntm price-to-earnings premium assumpt path assum recoveri
evid china definit virul elast initi fear appropri polici
measur report infect multipl intervent
jan feb slow lockdown traffic ban segment popul quarantin
home central quarantin measur report fallen feb
view line biotech team view though substanti risk point
dataset assum central quarantin assum path region
proxi us region level follow aei/gottlieb model emerg
track path recessiona close
let honest dont know recess play better understand dynam
impact tool vertic introduc high-frequ hifi index rapid turnov pmi
macro data find correl tool compani end market demand growth avail short lag
run methodolog gtmi seri aim flag inflect especi cyclic tool end market
demand march index growth deceler
best data avail track tool demand monthli weve track sever year
cut data come quickli given need rapid respons
compani data factset price wolf research
chang high-frequ composit vs ls tool applied/industri organ growth yoy ls tool organ industri revenue growth rh yoy appli organ growthyoy growth hf composit lh yoy chang indx stack average trade game framework take concis longitudin approach
trade game framework isol three key variabl across multipl recess recoveri period
provid perspect histor saniti check updat estim price target
histor perform top-line growth adjust structur chang compani end market
valuat rel ntm ev/ ebitda multipl base outlook
quintil approach three variabl look assess perform dispers perform
across coverag
cycl think drive lot want assum engin allow choos
adventur want live
ev ebitda multipl premium vs top quintil respect periodtool ev/ebitda premium vs respect ev ebitda multipl premium vs top quintil respect periodtool ev/ebitda premium vs respect period look back recess rel recent perform
coverag saw increas volatil addit recessionari perform
compani data factset wolf research note calendar year data includ agil
revenu growth quintilefirst quintilethird quintilemediansecond quintilel revenu growth quintilefirst quintilethird quintilemediansecond quintilel ebitda margin chang quintilefirst quintilethird quintilemediansecond quintilel ebitda margin chang quintilefirst quintilethird quintilemediansecond quintilel toolsdent estim reflect brief recess follow recoveri
view assum multi-month multi-quart covid event macro pressur remain
discretionari industri move anticip larg past acut downward pressur
game impli stock price versu current price impli price upsid downsid current pricel toolsdent crux underli dataset drive estim rel multipl
compani data factset wolf research note calendar year data includ agil
histor rel ev/datasetgrowthcompani specificebitda mgngrowthcompani specificebitda mgndataset forebitda mult companyfor estimatesref revenu adj ref periodref revenu adj ref periodrel mult ref periodtoolsagilentcompani bp mix shift bp easi sector china comp bp nasd scale bp nasd scale bp mix bp product cycl bp mix bp product cycl bp mix group bp market share gain bp lge molecul pharma bp mix shift bp three qtr cytiva ge acquisit bp bp market share gain bp lge molecul pharma bp mix shift bp cytiva ge full year group bp mix shift mix shift bp mix shift mix shift bp mix bp mix mix shift bp market share gain bp bioprocess bp bp market share gain bp bioprocess bp mix bp market share loss bp mix shift bp new product market share loss bp new product group bp industri price group bp industri price group bp industri price trend bp align scanner bp align scanner group bp industri price trend bp primescan primemil suresmil bp primescan primemil suresmil multipl hard pick lot growth situat variabl
rel ev/ebitda ntm multipl tool stock cycl center incorpor probabl
growth recoveri stock buoy nih stimulu fund valuat later temper macro
uncertainti european recess could re-appear dental ex-algn select period
saw broad macroeconom strength balanc structur headwind price dental segment
rel multipl look time-frame prior benefit itero faster growth busi
organ benefit approach util current ntm ev/ebitda multipl ytd
counterbal optim premium embed rel multipl recoveri period
compani data factset wolf research note calendar year data includ agil
rel premium ntm ev/ ebitda fourth quintilefirst quintilethird quintilemediansecond quintilel rel premium ntm ev/ ebitda fourth quintilefirst quintilethird quintilemediansecond quintilel rel premium ntm ev/ ebitda fourth quintilefirst quintilethird quintilemediansecond quintilel toolsdent trade game output impli coverag univers
indic tool trade game framework
indic dental trade game framework
impli price target dental group upsid averag current price
compani data factset wolf research note calendar year data includ agil previou estim
game impli chang estim price trade game output versu wolf estim chang impli price chang revenu chang revenu chang ebitda chang game impli chang estim price trade game output versu wolf estim chang impli price chang revenu chang revenu chang ebitda chang ebitda trade game output illustr drive point home
indic tool trade game framework
indic dental trade game framework
think tool evalu flaw object data-centr
compani data factset wolf research note calendar year data includ agil
previou estim refer estim
selectedimpli tradingtickercurr pricetrad game quintilegam price price vs curr price vs tg impli estimate price target vs wolf targetimpli tg ebitdachg prev ebitdaensu ebitda vs tg impli estimate impli tg saleschg prev salesensu salesselectedimpli tradingtickercurr pricetrad game quintilegam price vs wolf targetimpli tg ebitdachang prev ebitda tg price vs curr price price target ebitda vs tg impli estimate impli tg saleschang prev salesensu sale vs tg impli estimate life scienc tool rethink exposur matrix
adjust exposur matrix adjust at-risk
exposur includ academ govern
research govern budget risk margin
add non-china em exposur like domest
govern stimulu constraint region
remov net leverag small molecul qa/qc exposur
at-risk believ leverag fear amelior
medium-term sm/gener manufactur design
essenti busi lockdown scenario insul
end market measur includ pharma end
new framework agil
risk relat soft given signific
instrument mix exposur academ lab said
clear safe haven tool
note insul exposur includ estim total revenu exposur regul dx pharma end market at-risk includ exposur
academ gov cyclic end market ex-china em exposur averag at-risk instrument mix proxi like hardwar soft
pf forg ls pkitmowatmtdexposur insul vs at-risk growth end market insul growth exposureat-risk exposurenet at-risk revenu exposurecomposit at-risk end market exposur instrument mixtot at-risk composit servicesautomobil auto partsbanksmet miningchemicalshousehold person use productstransportationindustri goodssoftwar servicesr estatetechnolog equipmentbeverag foodindustri servicesinsuranceforestri paper productshealthcar servicespharma biotechih markit output index growth sinc previou month feb pmichina pmi life scienc tool risk vs recent return
tool stock held rel well relationship recent return riski posit
far ideal underappreci monetari dynam spend pressur
dental note net exposur reflect insul growth exposur medic low penetr dental segment develop market dso prevent
dental product high acuiti area at-risk exposur includ small dental practic aesthet area emerg market base consum credit
leverag risk anim health
compani data factset price wolf research
tool note insul exposur includ estim total revenu exposur regul dx pharma end market at-risk includ exposur
academ gov cyclic end market ex-china em exposur averag at-risk instrument mix proxi like hardwar soft
vs fundament risk exposur stock return exposuresmodel chang ebitda cyclic sensit tool dental end market
could sensit cycl look sensit index vs growth global
run beta calcul index vs growth seri lag covari two
set varianc growth
well correl acad-gov/dent index appear sensit cycl max
beta pharma index insul maximum beta take view near term
revis like acut academic/govern less acut pharma measur look
at-risk greater exposur risk pharma
 other cluster pharma best posit
relationship govern expenditur underappreci
chang acad-gov yoy chang base year ppp growth rh acad-gov qtlyapplied-industri qtlydent qtlydiagnost qtlypharma beta sensit correl cyclic sensit tool dental end market
shape curv recess unusu dental industri
chang dental yoy global ppp growth rh yoy growth chang pharma yoy chang base year ppp growth rh yoy growth chang applied-industri yoy chang base year ppp growth rh yoy growth chang diagnost yoy chang base year ppp growth rh yoy growth lh life scienc tool recent return group still look overvalu
within group long way go unwind risk avers multipl dispers
rel correct sinc last friday name perceiv high-qual remain near histor high
premia vs group prefer new-money idea within tool continu prefer
sinc tool group cap-weight wide narrow variat group vs
devic
shape curv recess unusu dental industri
compani data factset price wolf research
industri med-tech ls tool tmohealthcar dhrtools/sector stock return median ev/ebitda premium ev/ebitda flight safeti inflat multipl tmo/dhr vs
multipl converg last week spread remain wide
compani data factset price wolf research
price-to-earnings premium tool median median price-to-earnings premium tool median median price-to-earnings premium tool median median price-to-earnings premium tool median median median heard tool compani
elect procedur hospit dental practic impact covid-rel measur
pharma manufactur test manag suppli chain avoid covid-rel impact expect pharma
snapback
academ lab saw sever slowdown china lockdown scenario
realli know covid impact near term tough deferr hospital-deliv
structur posit diagnost hard capit good pharma bad industri
guid impactsm midpoint impact apac sale imp china declin china elect procedur feb/ impli impact apac sale total remain fy sept end delay softwar hardwar instal due fewer oncolog declin elect procedur china apac headwind cite lesser impli impact apac sale total guidanc contempl soft us eu china run rate maintain remaind exposuremaintain essenti build wuxi plant on-line past sever week manufactur x-ray lung screen devic -- hardest hit area seen lockdown impact almost procedur ex-elect stabil china trough europ meaning procedur slowdown region impact covid us -l impact apac calendar sale total slowdown oper cite management maintain full year msd outlook apac per week china apac/week total sale expect china msd hsd msd guid chang china sale growth msd guid apac impact apac sale total china dental clinic hospit remain close busi begin see impact apac impact apac sale impact part china dental clinic hospit remain close apac exposur shelter place measur mean expect larger neg impact us eu market shut still expect instrument back-load annual guid pull full year impact apac sale overal inact primarili china consum test audit inspect activ impact lab open apac exposureimpact expect less week extend chines new year holiday apac apac impact overal apac ls sale euro headwind life scienc impact china ls overal translat impact total life scienc apac exposureha experienc major disrupt suppli chain re-rout shipment work altern provid need -- clinic side seen increas activ pharma test academ lab saw shutdown china univers overal instal slowed/push -- us medic distributor maintain guidanc year readthrough distributor busi us -- varcnmdvarexmerck kgaamedtlonzasn-lonbvi-frsgsn-chtecanowen minoramtdxrayalgnbrkrzbhbsx dental rethink exposur matrix
revis dental exposur reflect long-term posit neg area dental compani
posit exposur driven growth opportun greater exposur develop market
dso expect equip sale aesthet clear align impact near-term defer
sensit econom outlook
stock return sinc somewhat track exposur gener reflect near-term impact
case overreact medium long-term impact manufactur harder hit
distributor equip leverag view import risk factor
matrix take long-term approach assum recess reflationari govern polici
labor market risk forecast assum slower spite polici action
note net exposur reflect insul growth exposur medic low penetr dental segment develop market dso prevent dental
product high acuiti area at-risk exposur includ small dental practic aesthet area emerg market base consum credit
leverag risk anim health
compani data factset price wolf research
insul vs at-risk growth end market insul growth exposureat-risk exposurenet vs fundament risk exposur stock return exposuresmodel chang ebitda dental updat get readi recess cycl data
soon see impact crisi data tell big impact
come month
servic spendingy/i medic dental equip manufacturingy/i stack spend usy/i stack labor market index flight safeti inflat multipl hsic/pdco vs xray/nvst
manufactur under-perform rel meaning
compani data factset price wolf research
price-to-earnings premium dental averag median price-to-earnings premium dental averag median price-to-earnings premium medic etf price-to-earnings median price-to-earnings premium medic etf price-to-earnings medianmedian sinc ipo dental countri level restrict
regul dental practic associ key market dental compani coverag
implement recommend delay elect prevent dental care expect impact sale much
dental manufactur distributor affect market
dentistri china particularli hard hit dentistri hospit china start
reopen dental clinic recov lost sale
countryrestrictiontimingimplicationunit statesadacallsforhalttoelectivecar includingcleaningsandradiograph non-emergencyorthodont extractionofasymptomat teeth fill asymptomat caviti aestheticsstart march acut ortho limit impact endo modest restor expect deferr summercanadanoguidefromthecanadiandentalassoci ontarioandquebecsocietiesencouragedelaystoelectiveandpreventivethrough end marchpressur acut ortho limit impact endo modest restor expect deferr summeraustralia new zealandaustraliaandnewzealandadviseelevatedinfectioncontrol symptom screen call case deferr nomin impact italyal movement restrictedthrough april laterhighli constrainingunit kingdomcutroutinecarefor vulnerablegroup consolidatingemerg care april-junemateri headwinddenmarkdelay non-emerg care monthson longer time periodsnetherlandssuspend routin careat least april dental volumesportugalemerg care april laterneg dental volumesaustriano suggest practic closuresmodestli positivechinadent clinic selec reopen february/march late marchcompani call normal volum return dental what essenti what
detail guidanc dso
broad set dental procedur
consid essenti
convers dental practic
dental
spend level normal
us europ practic
visit could greater
procedur gener higher cost
result
greater usag
implant
expect orthodont harder
treatment larg consid
near-term
dental commentari previou coronaviru outbreak
dental compani previou outbreak indic neg impact sar
compani point quick recoveri dental practic visit note previou commentari also
indic compani level result could volatil due inventori chang
medic segment near-term could neg impact lower traffic outpati clinic
physician offic partial off-set increas sale mask protect gear covid relat test
equip consum beyond near term benefit vaccin well
covid test clinician offic at-hom serolog test deploy
companytimingcommentend marketalgn -- mention sar impact materi busi small benefit medic mask sale suppliespdco -- mention sar impact sar sever key asian countri turn strongli posit region growth neg growth quarter specif dental busi china hong kong singapor taiwan drop sharpli due epidem therefor sale advers affect end second quarter dental visit return asia neg growth percent appear reflect inventori adjust asian dealer may recal first quarter report growth percent asia despit sar crisi hindsight dealer adjust order pattern rapidli enough sar crisi use third-quart reduc inventori normal level dentalnvst sdc public growth intern growth sale medic group physician area believ approxim half less half actual relat increas demand alreadi award bid sever us state distribut vaccin certain end user includ california largest arrang fee-for-servic basi moder profit us also expect littl bit head wind relat -- medic side less traffic physician offic versu last year relat patient traffic suppliesdent compani sar commentarydent compani commentari updat rate price target estim
compani data factset wolf research note fiscal year data agil
tickercurr pricecurr ratingprior ratingcurr price pricecurr ratingprior ratingcurr price chg prior ep estimate prior px targetcurr px wolf target con-sensu price target vs wolf target wolf epscurrentensu sale vs curr estimate ep vs curr estimate wolf salescurr chg prior sale estimate vs curr estimate ep vs curr estimate wolf salescurr chg prior sale estimate ensu sale prior px targetcon-sensu price target vs wolf target wolf epscurr chg prior ep estimate curr px wolf target life scienc tool agil maintain peer perform
maintain agil peer perform pt
agil remain uniqu expos chemic commod
price vs tool coverag maintain higher exposur capital-expenditure good
peer leav risk event ga chromatographi replac cycl
deferr phase oil price crude reach level
seen sinc cut lsag number new low top
reduct week prior time exposur basic pharma
manufactur key posit area believ experi continu
demand gener product continu servic diagnost spend
compar histori game hypothet take median revenu growth
preced growth benchmark recoveri given
less margin headroom recent downturn use median
ebitda growth proxi recoveri increment
previou cycl give agil mix shift benefit
easier china comp nasd scale-up
compani data factset wolf research note calendar year data includ agil
atrad game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda profitoper exp life scienc tool cut under-perform
cut under-perform peer perform pt
particularli expos complex capital-intens hardwar requir human
instal challeng given restrict lab activ moreov
expos academic/govern spend within group
instrument use discoveri work area check found
mostli shutdown could bounc back question tight capit get
margin expos academic/govern also
risk given pressur govern spend philanthrop invest pend
capit market risk also see compar smaller rel tailwind
regul test covid serolog drug product rel peer
compar histori game hypothet given uniqu volatil
brkr histor revenu ebitda growth compar challeng
posit vs peer take quintil revenu ebitda outcom
analog period model futur revenu ebitda growth use
compar give
benefici product cycl growth new research ms nmr
benefici mix shift
brkrtrade game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda life scienc tool cut peer perform
cut peer perform outperform cut pt
essenti valuat call dhr stock held better peer tool
healthcar result even greater valuat premium peer
estim reduct compar modest investor expect
uniqu high rel peer tool think expect tool peer
set doubl digit ep declin ep expect limit
recoveri scenario would prefer agil seriou
recess prefer leav us peer perform
compar histori game hypothet base strong recent
fundament perform use fourth quintil prior cycl
comparison estim revenu ebitda use
period forecast revenu ebitda margin chang adjust mix shift
bioprocess exposur core market share ge acquisit forecast
base cycl adjust multipl
base tool group rel multipl assum declin
multipl recent trade sharp premium group
dhrtrade game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda revenu dilut life scienc tool cut under-perform
cut under-perform peer perform lower pt
mtd busi mix shift posit vs prior cycl mtd
valuat premium sharpli expand expect slower recoveri
vs peer greater pharma product diagnost posit
note exposur auto true industri area
modest uniqu concern margin
compar histori game hypothet use
median prior period includ cycl revenu declin
ebitda margin forecast use median
cycl revenu growth forecast year adjust
reflect mix shift away core industri laboratori
life scienc exposur use mtd histor premium market
time-frame premium market multipl use
mtdtrade game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda revenu dilut life scienc tool perkinelm maintain peer perform
maintain peer perform pt
exposur matrix slide find pki posit uniqu difficult
handicap rel insul vs peer given overindex regul
diagnost underindex academic/govern spend though highlight
like lost revenu trimest reproduct test affect area
exposur em put greater risk depress demand
trough commod trend domest stimulu measur ex-imf
unlik despit believ pki low instrument mix high infecti dx
pharma servic euroimmun test exposur posit
snap-back strongli
compar histori game hypothet revenu ebitda
growth use quintil growth benchmark given
concern em fund trend also give increment
benefit vs signific mix shift toward dx pharma
end market acquisitions/divestitur imag euroimmun
note model chang also includ addit earn
maintain outperform pt remain
tmo pharma exposur share gain diagnost posit share gain
uniqu attract exposur academ govern spend
highest coverag end market could leav vulner tighter univers
trend govern budget mute upsid price target held
vs peer said expect tailwind spec dx
top-lin benefit healthi
pharma exposur remain posit transact expect
molecular dx invest acceler given covid crisi
compar histori
game hypothet select
quintil
revenu growth analog top-lin could return
use quintil ebitda recoveri model
model also revenu benefit
posit mix shift life scienc project market share gain
increment bioprocess revenu gain vs adjust
tmo anatom patholog divestitur worth roughli henc
differenti model chang output trade game
maintain under-perform pt
see mix impact covid crisi could rel net
beneficiari larg qa/qc pharma manufactur exposur offset
industri trend drag thermal analysi busi hardwar given
seen februari pmi recent gener volum data news drug
product mandat essenti busi increas estim lc
column consum previou
maintain
under-perform see less downsid vs histori
compar histori game hypothet revenu growth use
benchmark howev given view
near peak margin use quintil ebitda growth histor
preced
wattrad game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda dental bridg covid impact
forecast impact practic closur dental compani base region
exposur expect length shutdown region expect recoveri sale region
also factor impact spend discretionari purchas patient dental practic
acut effort assum practic closur run roughli mid-may
adjust estim recent note
maintain outperform rate rais
price target model unchang
note orthodont somewhat deferr continu
view best way play mix shift align
bracket trend persist independ macro
compar histori game hypothet
use compani growth cycl revenu impact
use ebitda margin chang ebitda
use cycl forecast period
period ebitda margin chang revenu
could hit harder histor trend uniqu
combin practic closur econom trend
neg near-term use histor premium
market period premium use
calcul ev/ebitda multipl impli share price
algntrad game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda board us con conf algn america volum growth lh y/i average consum confidenceforecastorthodontistgptotalteen dental maintain outperform
expect remain high stock spite near-
term impact practic closur macro weak
underli growth next month like
remain strong secular tailwind
note model chang reflect chang made prior note
salesimpactapac total total revenu dilut dental dentsply-sirona rais outperform
rais rate outperform peer perform
increas pt
believ investor taken xray commentari apac
revenu neg data point dental revenu
world-wide overli depress valuat expect market
less impact believ share attract
result declin share prime cycl like
delay remain posit opportun
compar histori game hypothet use
compani growth baselin neg adjust
industri price trend also use ebitda margin
chang ebitda use cycl forecast
period period ebitda margin chang
use xray histor premium market
period premium use calcul ev/ebitda multipl
impli share price
adjust estim recent note
maintain outperform rate rais
price target adjust
time impact updat
note
discuss major overhang
drag stock year view concern
covid impact world-wide leverag overdon
acut expect resolv debt coven
sentiment overhang
compar histori game hypothet
use dental group growth rate
cycl revenu impact margin
neg adjust industri price trend compar
time period partial off-set benefit new
product use cycl forecast period
revenu ebitda margin chang use
dental median histor premium market
period premium use calcul
ev/ebitda multipl impli share price
compani data factset wolf research note model chang reflect chang prior note revis effort
trade game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda revenu dilut debt covenantleverag ratio net debt leverag adj net debt leverag leverag ratio quarter ebitda hit leverag ratio requir ebitda declin hit leverag ratio gross revenu declin gross margin drop impli declin revenu vs dental rais outperform
rais rate outperform under-perform
lower pt like dental peer come
pressur dental sentiment
expect resolv
cours year note medic segment
less impact compani compani
benefit sale safeti equip balanc
year alongsid diagnost test offset neg impact
lower volum outpati set near term
compar histori game hypothet use
dental group growth rate cycl revenu impact
margin neg adjust
industri price
trend compar time period use compani histori
cycl forecast period revenu ebitda
margin chang use compani histor premium market
period premium use calcul
ev/ebitda multipl impli share price
hsictrad game impli estimatestrad game impli upsidequintilerevenuesrevenuesebitda mgnebitdaebitda dental patterson co rais peer perform
rais rate peer perform under-perform
maintain pt
improv fundament
perform salesforc execut effort yet sold
dental group posit less attract discretionari
compar histori game hypothet use
dental group growth rate cycl revenu impact
margin neg adjust
industri price
trend compar time period use compani histori
cycl forecast period revenu ebitda
margin chang use compani histor premium market
period premium use calcul
ev/ebitda multipl impli share price
compani data factset wolf research note calendar year data includ agil
compani data factset price wolf research
compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool yieldfcf compound-annual-growth-rate compound-annual-growth-rate cap healthcar price-to-earnings vs ep compound-annual-growth-rate valuat tool compani rel tangenti industri
compani data factset price wolf research
price-to-earnings premium healthcar price-to-earnings premium industri median ev/ebitda premium price-to-earnings premium devic price-to-earnings life scienc tool end market exposur detail
total life scienceacademic/gov tpharmatot regulateddiagnosticsfoodenvironmentalforensics/othertot cyclicalenergy/ chemdiagnosticsfoodenvironmentaloth pharma salescro/cdmo salesr mfg small mol qa/qcsoftware/ servicessmal mol biotech/ larg pf ge exposur sub-categorytot cyclic saleschemicalsoil gasfoodenv semiconductorsgeneral/oth exposur sub-categoryacademic/govern split industri comp
compani data factset price wolf research
targetorganicdebt /compani nametickerratingcurr pricefor ye market floatday ex small scienc tool wolf lst ex small wr life scienc tool dental p/efcf yieldev/salesev/ebitdarecommendationsshort interest appendix incom statement agil
cog gross interest non common dilut margin appendix incom statement danah
 pre profit continu adj ep tax appendix incom statement perkinelm
excl deal relat share fulli ebit increment appendix incom statement water
 cog gross margin sales/mktg total opex non-gaap adjust non-gaap ebit interest/oth equiti sdc non-oper pre-tax incom non-gaap pre-tax incom tax non-gaap tax tax net incom non-gaap net incom dilut share dilut dilut margin appendix incom statement dentsply-sirona
metal margin inc pre-tax tax unconsolid net non incom net cont dilut non margin appendix incom statement envista
envista non-gaap ebitda margin bpsgaap adj share non-gaap growth margin bpsorgan appendix incom statement
 gross margin oper inc pre-tax tax net incom net continu dilut margin appendix incom statement patterson corp
gross margin op inc exp inc pre-tax tax net cont dilut margin cont organ margin disclosur section
